In a significant development for the oncology pharmaceutical patent landscape, BeiGene USA, Inc. and BeiGene Switzerland GmbH filed a patent infringement action against Sandoz, Inc. in the U.S. District Court for the District of New Jersey on March 8, 2024, asserting three patents—US10927117B2, US11591340B2, and US11851437B2—covering their commercially successful BTK inhibitor BRUKINSA® (zanubrutinib) capsules, 80 mg. The case, docketed as 3:24-cv-01972, was closed on August 15, 2024, just 160 days after filing, when both parties stipulated to dismissal without prejudice under Federal Rule of Civil Procedure 41(a) and (c), with each side bearing its own costs and attorneys’ fees.

This case carries meaningful strategic weight for IP professionals navigating the increasingly competitive BTK inhibitor market, where generic entry timing can reshape billions in revenue. The dismissal without prejudice leaves all patent claims and counterclaims legally unresolved, preserving BeiGene’s right to re-assert its zanubrutinib patent portfolio and signaling that negotiated resolution—or a strategic repositioning—may have occurred outside the public record. Patent attorneys, in-house IP teams, and R&D leaders working in small-molecule oncology should closely monitor subsequent filings involving these three patents.

Case Overview

The Parties

The Patents at Issue

The three patents at issue—US10927117B2, US11591340B2, and US11851437B2—relate to zanubrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor used to treat B-cell malignancies such as mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia. These patents collectively cover the chemical compound itself, specific pharmaceutical formulations (including the 80 mg capsule dosage form), and potentially methods of treatment or synthesis, providing layered intellectual property protection around the BRUKINSA® product franchise. Together, they form a patent thicket that generic manufacturers must navigate before commercializing a competing zanubrutinib product in the United States.

• • US10927117B2
• • US11591340B2
• • US11851437B2

Legal Representation

Plaintiff Counsel: Walsh Pizzi O’Reilly Falanga LLP (lead: Katelyn O’Reilly)
Defendant Counsel: Hill Wallack LLP (lead: Eric I. Abraham)

Litigation Timeline & Procedural History

This case was filed in the U.S. District Court for the District of New Jersey—the preeminent venue for Hatch-Waxman pharmaceutical patent litigation in the United States, home to a deeply experienced bench in ANDA cases and frequently chosen by branded pharmaceutical companies due to its procedural familiarity with the 30-month stay framework. As a first-instance district court proceeding, the case would have proceeded through claim construction, fact discovery, and expert discovery before any merits ruling, making early resolution particularly common at this stage when parties gain clarity on the strength of their respective positions.

The case spanned just 160 days from filing on March 8, 2024, to closure on August 15, 2024—a notably short duration for pharmaceutical patent litigation, which typically unfolds over two to four years. This compressed timeline strongly suggests the parties reached an agreement, whether a settlement, licensing arrangement, or consent judgment, outside the courtroom. The basis of termination—a stipulated dismissal without prejudice under Federal Rules of Civil Procedure 41(a) and (c), with each party bearing its own costs—is a hallmark of negotiated resolution, as it preserves BeiGene’s ability to refile and may reflect an agreed-upon generic entry date or a covenant not to sue, the terms of which were not disclosed in the public record.

The Verdict & Legal Analysis

Outcome

The action was terminated on August 15, 2024, via a joint stipulation of dismissal without prejudice executed by all parties pursuant to Federal Rules of Civil Procedure 41(a) and (c), meaning no court ruling was issued on the merits of the infringement claims or any invalidity counterclaims asserted by Sandoz. No damages were awarded, no injunctive relief was granted, and no claim construction order was issued. Each party was directed to bear its own costs, expenses, and attorneys’ fees, a cost-neutral resolution consistent with a privately negotiated outcome.

Verdict Cause Analysis

The following analysis examines the key legal and procedural dimensions of this stipulated infringement action and what they reveal about the underlying patent dispute strategy.

• The infringement action was brought under the Hatch-Waxman Act framework, where BeiGene’s filing of suit within 45 days of receiving Sandoz’s Paragraph IV certification notice would have triggered an automatic 30-month stay of FDA approval for the generic zanubrutinib product.
• The stipulated dismissal without prejudice under Rule 41(a) and (c) preserves BeiGene’s full right to re-assert all three patents—US10927117B2, US11591340B2, and US11851437B2—in future proceedings, leaving Sandoz’s generic entry pathway legally unresolved on the public record.
• The cost-neutral allocation, where each party bears its own attorneys’ fees and expenses, is characteristic of a mutually agreed resolution rather than a unilateral concession, suggesting neither party viewed continued litigation as strategically optimal at this stage.
• The involvement of three distinct patents covering different aspects of the zanubrutinib franchise (compound, formulation, and potentially method claims) created a complex multi-patent landscape that may have incentivized early resolution over a costly multi-year litigation track.

Legal Significance

1. A dismissal without prejudice in a Hatch-Waxman ANDA case does not constitute a legal determination of patent validity or enforceability, meaning all three BeiGene zanubrutinib patents remain fully presumed valid under 35 U.S.C. § 282 and can be asserted against Sandoz or other ANDA filers in future actions.
2. The resolution of this case within 160 days—well before the expiration of the typical 30-month Hatch-Waxman stay—suggests that any agreed generic entry date, if one was negotiated, would be governed by a private settlement agreement rather than any publicly binding court order, limiting the precedential visibility of this outcome for other generic challengers.
3. The three-patent assertion strategy employed by BeiGene, spanning application numbers US16/325447, US17/740882, and US17/901951, reflects a layered portfolio approach common in blockbuster drug defense that other innovator companies can model when structuring Orange Book listings to maximize litigation leverage against ANDA filers.

Strategic Takeaways

For Patent Attorneys:

• When counseling branded pharmaceutical clients, advocate for multi-patent assertion strategies that span compound, formulation, and method-of-use claims across multiple Orange Book-listed patents, as BeiGene’s three-patent approach here created maximum litigation complexity for Sandoz and likely strengthened settlement leverage.
• The Rule 41(a)/(c) stipulated dismissal without prejudice is a powerful tool in Hatch-Waxman settlements—it preserves the plaintiff’s right to refile while enabling confidential licensing terms, and attorneys should ensure any such dismissal is carefully paired with a robust covenant-not-to-sue or license agreement to protect client interests.
• Monitor the FDA’s Orange Book and ANDA docket for subsequent Paragraph IV certifications against US10927117B2, US11591340B2, and US11851437B2 from other generic filers, as the unresolved dismissal here may embolden new challengers who perceive an absence of judicial validation of these patents.
• In drafting future zanubrutinib-related patent applications in this family (continuation applications descending from US16/325447, US17/740882, and US17/901951), consider broadening independent claims to encompass generic formulation approaches that Sandoz or other ANDA filers may have disclosed in their certifications.

For IP Professionals:

• In-house IP teams at innovator pharmaceutical companies should treat this case as a model for aggressive but strategically flexible portfolio defense—listing multiple patents in the Orange Book across different claim types creates maximum procedural leverage while retaining the option for confidential resolution before costly merits litigation.
• BeiGene’s IP team should implement a structured monitoring protocol for all three asserted patents—US10927117B2, US11591340B2, and US11851437B2—tracking any new ANDA filings, IPR petitions, or ex parte reexamination requests that could undermine the patent thicket protecting BRUKINSA® revenue through its commercial lifecycle.

For R&D Teams:

• R&D teams at generic pharmaceutical companies seeking to develop zanubrutinib alternatives should commission a thorough freedom-to-operate analysis against the entire BeiGene patent family, as the dismissal without prejudice leaves these three patents fully enforceable and BeiGene retains the right to refile against any party that commercially launches a competing product.
• Research teams exploring next-generation BTK inhibitors or alternative zanubrutinib dosage forms should document design-around efforts contemporaneously, as claim scope in US10927117B2, US11591340B2, and US11851437B2 may extend beyond the 80 mg capsule form to encompass structurally related compounds or formulation variations.